Clinical Trials Browser

Active not recruiting × Breast Neoplasms × 2C4 antibody × Clear all

NCT02827877 2025-11-14

Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer

Phase 2 Active not recruiting

18 enrolled 8 charts

Breast Neoplasms